Is ALLO or ABOS more profitable?

Allogene Therapeutics' return on equity of -56.45% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Acumen Pharmaceuticals N/A -123.07% -79.41%

Does the media favor ALLO or ABOS?

In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 3 articles in the media. Allogene Therapeutics' average media sentiment score of 1.19 beat Acumen Pharmaceuticals' score of 0.56 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ABOS or AURA?

Aura Biosciences is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Aura Biosciences N/A N/A -$106.19M -$1.74 N/A

Is ABOS or AURA more profitable?

Aura Biosciences' return on equity of -78.12% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Aura Biosciences N/A -78.12% -64.08%

Does the media refer more to ABOS or AURA?

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 3 articles in the media. Aura Biosciences' average media sentiment score of 0.83 beat Acumen Pharmaceuticals' score of 0.56 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRME or ABOS?

In the previous week, Prime Medicine had 5 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 8 mentions for Prime Medicine and 3 mentions for Acumen Pharmaceuticals. Prime Medicine's average media sentiment score of 0.85 beat Acumen Pharmaceuticals' score of 0.56 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ABOS or CADL?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is ABOS or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Candel Therapeutics N/A -60.42% -41.33%

Does the media prefer ABOS or CADL?

In the previous week, Candel Therapeutics had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 5 mentions for Candel Therapeutics and 3 mentions for Acumen Pharmaceuticals. Candel Therapeutics' average media sentiment score of 1.03 beat Acumen Pharmaceuticals' score of 0.56 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ABOS or TECX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is ABOS or TECX more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Tectonic Therapeutic N/A -32.33% -30.92%

Does the media prefer ABOS or TECX?

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 3 mentions for Acumen Pharmaceuticals and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.61 beat Acumen Pharmaceuticals' score of 0.56 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Acumen Pharmaceuticals (ABOS) Competitors

$2.64 +0.01 (+0.38%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$2.68 +0.04 (+1.70%)

As of 08:46 AM Eastern

Compare

ABOS vs. ALLO, AURA, PRME, CADL, and TECX

Should you buy Acumen Pharmaceuticals stock or one of its competitors? MarketBeat compares Acumen Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acumen Pharmaceuticals include Allogene Therapeutics (ALLO), Aura Biosciences (AURA), Prime Medicine (PRME), Candel Therapeutics (CADL), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry.

How does Acumen Pharmaceuticals compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Allogene Therapeutics currently has a consensus price target of $8.52, indicating a potential upside of 341.57%. Acumen Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 203.03%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Allogene Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 3 articles in the media. Allogene Therapeutics' average media sentiment score of 1.19 beat Acumen Pharmaceuticals' score of 0.56 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Allogene Therapeutics' return on equity of -56.45% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Acumen Pharmaceuticals has lower revenue, but higher earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	33,306.98	-$190.89M	-$0.77	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Summary

Allogene Therapeutics beats Acumen Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Aura Biosciences?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Acumen Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Aura Biosciences' return on equity of -78.12% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Aura Biosciences	N/A	-78.12%	-64.08%

Aura Biosciences is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Acumen Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 203.03%. Aura Biosciences has a consensus price target of $20.50, indicating a potential upside of 192.86%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Acumen Pharmaceuticals is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Acumen Pharmaceuticals and Acumen Pharmaceuticals both had 3 articles in the media. Aura Biosciences' average media sentiment score of 0.83 beat Acumen Pharmaceuticals' score of 0.56 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aura Biosciences beats Acumen Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

In the previous week, Prime Medicine had 5 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 8 mentions for Prime Medicine and 3 mentions for Acumen Pharmaceuticals. Prime Medicine's average media sentiment score of 0.85 beat Acumen Pharmaceuticals' score of 0.56 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prime Medicine presently has a consensus price target of $7.53, suggesting a potential upside of 114.57%. Acumen Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 203.03%. Given Acumen Pharmaceuticals' higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Acumen Pharmaceuticals has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	136.93	-$201.14M	-$1.23	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

Acumen Pharmaceuticals has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Acumen Pharmaceuticals' return on equity of -123.07% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Prime Medicine has a beta of 2.26, meaning that its stock price is 126% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Summary

Prime Medicine beats Acumen Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Candel Therapeutics?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Acumen Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 203.03%. Candel Therapeutics has a consensus price target of $18.57, indicating a potential upside of 92.65%. Given Acumen Pharmaceuticals' higher probable upside, equities analysts clearly believe Acumen Pharmaceuticals is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Candel Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Candel Therapeutics' return on equity of -60.42% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Candel Therapeutics	N/A	-60.42%	-41.33%

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Candel Therapeutics had 2 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 5 mentions for Candel Therapeutics and 3 mentions for Acumen Pharmaceuticals. Candel Therapeutics' average media sentiment score of 1.03 beat Acumen Pharmaceuticals' score of 0.56 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acumen Pharmaceuticals has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.52, meaning that its share price is 152% less volatile than the broader market.

Summary

Candel Therapeutics beats Acumen Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Acumen Pharmaceuticals compare to Tectonic Therapeutic?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Tectonic Therapeutic's return on equity of -32.33% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 203.03%. Tectonic Therapeutic has a consensus target price of $79.40, indicating a potential upside of 131.22%. Given Acumen Pharmaceuticals' higher possible upside, equities analysts plainly believe Acumen Pharmaceuticals is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 3 mentions for Acumen Pharmaceuticals and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.61 beat Acumen Pharmaceuticals' score of 0.56 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Acumen Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, indicating that its share price is 221% more volatile than the broader market.

Summary

Tectonic Therapeutic beats Acumen Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Acumen Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABOS vs. The Competition

Export

Metric	Acumen Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$189.96M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.42	20.85	27.11	24.26
Price / Sales	N/A	314.01	589.18	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	2.28	8.49	10.73	6.29
Net Income	-$121.33M	$23.83M	$3.58B	$330.66M
7 Day Performance	2.72%	-3.56%	-2.11%	-1.35%
1 Month Performance	11.39%	6.31%	3.27%	-0.64%
1 Year Performance	77.18%	48.30%	26.32%	19.08%

Acumen Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABOS Acumen Pharmaceuticals	2.3313 of 5 stars	$2.64 +0.4%	$8.00 +203.0%	+88.6%	$189.96M	N/A	N/A	20	Analyst Downgrade
ALLO Allogene Therapeutics	2.4023 of 5 stars	$2.10 +0.2%	$8.52 +306.8%	+50.8%	$726.54M	$20K	N/A	310	News Coverage Positive News
AURA Aura Biosciences	2.1887 of 5 stars	$6.97 -1.8%	$20.50 +194.3%	+9.4%	$722.08M	N/A	N/A	50	Analyst Downgrade
PRME Prime Medicine	3.1858 of 5 stars	$3.99 +0.1%	$7.53 +88.6%	N/A	$719.76M	$4.03M	N/A	N/A	News Coverage Gap Down
CADL Candel Therapeutics	3.3327 of 5 stars	$9.67 -3.6%	$18.00 +86.2%	+65.9%	$709.91M	N/A	N/A	60	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABOS) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. ALLO, AURA, PRME, CADL, and TECX

How does Acumen Pharmaceuticals compare to Allogene Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to Aura Biosciences?

Summary

How does Acumen Pharmaceuticals compare to Prime Medicine?

Summary

How does Acumen Pharmaceuticals compare to Candel Therapeutics?

Summary

How does Acumen Pharmaceuticals compare to Tectonic Therapeutic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acumen Pharmaceuticals (ABOS) Competitors

ABOS vs. ALLO, AURA, PRME, CADL, and TECX

How does Acumen Pharmaceuticals compare to Allogene Therapeutics?

Do analysts rate ALLO or ABOS?

Does the media favor ALLO or ABOS?

Do institutionals & insiders have more ownership in ALLO or ABOS?

Is ALLO or ABOS more profitable?

Which has more volatility and risk, ALLO or ABOS?

Which has better valuation & earnings, ALLO or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Aura Biosciences?

Which has more risk & volatility, ABOS or AURA?

Is ABOS or AURA more profitable?

Which has preferable earnings & valuation, ABOS or AURA?

Do institutionals & insiders believe in ABOS or AURA?

Do analysts rate ABOS or AURA?

Does the media refer more to ABOS or AURA?

Summary

How does Acumen Pharmaceuticals compare to Prime Medicine?

Does the media refer more to PRME or ABOS?

Do analysts prefer PRME or ABOS?

Which has stronger valuation & earnings, PRME or ABOS?

Is PRME or ABOS more profitable?

Do insiders and institutionals have more ownership in PRME or ABOS?

Which has more risk & volatility, PRME or ABOS?

Summary

How does Acumen Pharmaceuticals compare to Candel Therapeutics?

Do analysts recommend ABOS or CADL?

Which has preferable valuation & earnings, ABOS or CADL?

Is ABOS or CADL more profitable?

Do institutionals and insiders believe in ABOS or CADL?

Does the media prefer ABOS or CADL?

Which has more volatility & risk, ABOS or CADL?

Summary

How does Acumen Pharmaceuticals compare to Tectonic Therapeutic?

Which has better valuation & earnings, ABOS or TECX?

Is ABOS or TECX more profitable?

Do institutionals and insiders believe in ABOS or TECX?

Do analysts prefer ABOS or TECX?

Does the media prefer ABOS or TECX?

Which has more risk and volatility, ABOS or TECX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS vs. The Competition

Acumen Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools